AlphaLife Sciences

DIA 2026 · Jun 14–18 · Philadelphia

AuroraPrime · DIA 2026 strategic prep

AuroraPrime · DIA 2026 主舞台战略准备

Talk: AI-Augmented Lifecycle · Study Design → eCTD

DIA 2026 Strategic PrepDIA 2026 战略准备

AuroraPrime's view on DIA 2026 (June 14–18, 2026, Pennsylvania Convention Center, Philadelphia, PA) — what to say on stage, who to neutralize, what to anchor.

AuroraPrime 对 DIA 2026 的全景视图:登台说什么、压制谁、引用什么权威。

DIA tracks

议程主题

10

10 (down from 12 in 2025, 13 in 2024)

Vendors profiled

厂商档案

9

7 AI-native · 2 incumbent

7 家 AI 原生 · 2 家平台守成

Pharma signals

药企信号

20

6 Tier 1 + 14 Tier 2-3

6 家 Tier 1 + 14 家 Tier 2-3

Watershed reg signals

分水岭监管信号

3

EMA-FDA Joint · ICH M11 · AIM-NASH

EMA-FDA 联合原则 · ICH M11 · AIM-NASH

AuroraPrime stage positioning主舞台站位

AI-Augmented Lifecycle: from Study Design to eCTD-Ready Submission, in one AI-native platform.AI 全流程平台:从研究设计到 eCTD 就绪递交的端到端 AI 解决方案。

End-to-endAI-nativeFDA · EMA · PMDA · NMPADemo · not slideware

Sections分析章节

Click into each for detailed charts, tables, and source data.

点击进入每个章节查看详细图表、表格与数据来源。

01 · Program & Keywords01 · 议程与关键词

What DIA's marketing layer saysDIA 营销层说了什么

10

tracks议程主题

2/4

AI keynotesAI 主题演讲

6

white-space terms话语空白词

Top mentioned keywords高频关键词

AI / Artificial Intelligence · 9Generative AI / GenAI · 2Pharmacovigilance / Safety · 2Medical Writing · 1Lifecycle / End-to-end · 1

02 · Vendor Landscape02 · 厂商格局

Who else is on the floor同场还有谁

9 DIA 2026 presenting vendors mapped on a 6-dimension lifecycle — AuroraPrime is the only row that is full across every column.

9 家在 DIA 2026 演讲的厂商映射到 6 个生命周期维度 — AuroraPrime 是唯一一行在每一列都全覆盖。

Artos AIYseopCertara (CoAuthor)CollateVivpro Corporation (REGAIN)Weave Bio+3

03 · Pharma Priorities03 · 药企优先级

What the buyers actually care about买方真正关心的是什么

Top AI prioritiesTop AI 优先级

1.AI-driven drug discovery / target ID / molecule designAI 驱动药物发现 / 靶点 / 分子设计
2.GenAI for medical affairs, MLR, content productionGenAI:医学事务、MLR、内容生产
3.Agentic / 'copilot' AI for R&D operations智能体 AI 助手:临床运营、PV、数据管理

Top blocker最大阻碍

Hallucination risk in regulated content

幻觉风险(监管内容)

04 · Regulatory Trends04 · 监管趋势

Where the regulators are moving监管走向何处

1.AI in regulated submissions监管递交中的 AI
2.Agentic AI in pharma药企智能体 AI
3.ICH M11 (CTD-Protocol)ICH M11(CTD-方案模板)
4.eCTD v4.0 transitioneCTD v4.0 过渡

+ 2 more+ 还有 2

Narrative slots to claim可占据的话语空白

Themes structurally relevant to AuroraPrime that DIA 2026 marketing has left blank.

DIA 2026 营销层留白,但与 AuroraPrime 高度相关的话语主题。

white space

End-to-end AI lifecycle: study design → eCTD

端到端 AI 全生命周期:研究设计 → eCTD

Direct match to AuroraPrime talk title — own this slot.

与 AuroraPrime 演讲标题完全契合——抢占这个空位。

white space

eCTD-readiness as an AI output

eCTD 就绪作为 AI 输出

Differentiator vs. all 'GenAI for pharma' talks that stop at 'draft a section'.

相对于所有「停留在写几段草稿」的 GenAI for pharma 演讲,这是清晰的差异化点。

white space

ICH M11 operationalization

ICH M11 落地实施

Use M11 as the technical anchor that makes the talk credible.

用 M11 作为技术锚点,让演讲更具可信度。